Condition: Eye Abnormalities · Sponsor: University Hospital, Toulouse
Ocular morphogenesis is a complex process starting as early as the 4th week of embryonic life, involving interactions between varioustissues of different origin and conserved genes. Anomalies in ocular development , often of genetic origin, pose diagnostic and therapeutic challenges. Animal models are limited, so human-induced pluripotent stem cell (hiPSC)-derived optic vesicle containing brain organoids (OVBOs) offer a promising alternative. These pathological OVBOs, created from patients' cells with ocular malformations, allow for the study of underlying molecular mechanisms and testing of therapies.
This description comes directly from the study's public registry record.
Julie Plaisancie, MD, PhD · 0561779075 · plaisancie.j@chu-toulouse.fr
Always discuss trial participation with your own doctor first.
| CHU de Clermont-Ferrand - Hôpital d'Estaing | Clermont-Ferrand, France | Recruiting |
| Purpan University Hospital | Toulouse, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06408701